SVRA — Savara Inc. Stock Price, Chart & AI Report

Positive Feb 4, 2026 • 21:05 UTC Benzinga • Business Wire

Savara Announces Participation in Upcoming Investor Healthcare Conferences

Savara Inc. (NASDAQ: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, announced that its management team will participate in one-on-one meetings and fireside chats at two upcoming investor healthcare conferences. The company's lead program, MOLBREEVI, is a recombinant human GM-CSF in Phase 3 development for autoimmune pulmonary alveolar proteinosis (autoimmune PAP).

SVRA biopharmaceutical rare respiratory diseases clinical stage investor conference MOLBREEVI autoimmune PAP Phase 3

Sentiment note

The company is advancing its lead program MOLBREEVI to Phase 3 development and actively engaging with investors at healthcare conferences, demonstrating progress in clinical development and investor relations activities for a rare disease treatment.

Negative Jan 24, 2026 • 16:38 UTC GlobeNewswire Inc. • Bragar Eagel & Squire, P.C.

SAVARA INVESTIGATION ALERT: Bragar Eagel & Squire, P.C. is Investigating Savara, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

Law firm Bragar Eagel & Squire is investigating Savara, Inc. for potential breach of fiduciary duties by its board of directors. The investigation concerns allegations that Savara failed to disclose that its MOLBREEVI BLA lacked sufficient information regarding chemistry, manufacturing, and controls, making FDA approval unlikely. On May 27, 2025, the FDA issued a refusal to file letter, causing Savara's stock to plummet 31.69% to $1.94 per share. The class action covers the period from March 7, 2024 to May 23, 2025.

SVRA class action lawsuit fiduciary duty breach FDA refusal to file MOLBREEVI BLA stock price decline disclosure failure shareholder investigation

Sentiment note

The company faces a class action investigation for allegedly failing to disclose material information about regulatory deficiencies in its lead drug candidate MOLBREEVI. The subsequent FDA rejection letter resulted in a severe 31.69% stock price decline, indicating significant investor losses and loss of confidence in the company's management and disclosure practices.

Positive Dec 17, 2025 • 13:05 UTC Benzinga • Business Wire

Savara Announces Participation in the 44th Annual J.P. Morgan Healthcare Conference

Savara Inc., a clinical-stage biopharmaceutical company focused on rare respiratory diseases, will present at the 44th Annual J.P. Morgan Healthcare Conference. The company's lead program, MOLBREEVI, is a Phase 3 development treatment for autoimmune pulmonary alveolar proteinosis.

SVRA biopharmaceutical respiratory diseases healthcare conference MOLBREEVI pulmonary alveolar proteinosis

Sentiment note

The company is actively presenting at a major healthcare conference and advancing a lead program in Phase 3 development, indicating progress and potential growth

Neutral Nov 20, 2025 • 21:05 UTC Benzinga • Business Wire

Savara Announces Participation in Upcoming Investor Healthcare Conferences

Savara Inc., a clinical-stage biopharmaceutical company focused on rare respiratory diseases, will participate in upcoming healthcare investor conferences, hosting one-on-one meetings and fireside chats.

SVRA healthcare conferences respiratory diseases biotechnology

Sentiment note

The company is presenting at investor conferences, which suggests ongoing business activities and potential investor engagement, but no significant positive or negative developments are highlighted

Negative Nov 7, 2025 • 07:22 UTC Benzinga • Prnewswire

SVRA Investors Have Opportunity to Lead Savara Inc. Securities Fraud Lawsuit with the Schall Law Firm

The Schall Law Firm is pursuing a class action lawsuit against Savara Inc. for allegedly making false and misleading statements about their BLA (Biologics License Application) for MOLBREEVI, which was deemed insufficient by the FDA and likely to require additional capital.

SVRA securities fraud lawsuit BLA FDA investor rights

Sentiment note

The company is accused of providing inadequate information to the FDA for their drug application, making false statements to the market, and potentially causing investor financial losses

Negative Nov 6, 2025 • 01:57 UTC GlobeNewswire Inc. • Rosen Law Firm

SVRA DEADLINE: ROSEN, NATIONALLY REGARDED INVESTOR COUNSEL, Encourages Savara Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important November 7 Deadline in Securities Class Action– SVRA

Rosen Law Firm alerts Savara Inc. investors about a securities class action lawsuit regarding potential misleading statements about a clinical trial's regulatory approval process, with a November 7, 2025 lead plaintiff deadline.

SVRA securities class action FDA clinical trial regulatory approval

Sentiment note

The lawsuit alleges the company made false or misleading statements about its MOLBREEVI clinical trial's Biologics License Application, suggesting potential regulatory challenges and potential need for additional capital raising

Positive Nov 3, 2025 • 21:05 UTC Benzinga • Business Wire

Savara Announces Participation in Upcoming Investor Healthcare Conferences

Savara Inc., a clinical-stage biopharmaceutical company focused on rare respiratory diseases, will participate in upcoming healthcare investor conferences, hosting meetings and fireside chats to discuss their lead program MOLBREEVI.

SVRA healthcare conferences respiratory diseases biotechnology investor relations

Sentiment note

The company is actively engaging with investors, showcasing its lead program MOLBREEVI in Phase 3 development, and demonstrating management's experience in rare respiratory diseases

Negative Nov 2, 2025 • 23:47 UTC GlobeNewswire Inc. • Rosen Law Firm

SVRA DEADLINE: ROSEN, HIGHLY RANKED INVESTOR RIGHTS COUNSEL, Encourages Savara Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important November 7 Deadline in Securities Class Action– SVRA

Rosen Law Firm is alerting Savara Inc. investors about a securities class action lawsuit regarding potential misleading statements about a clinical trial's regulatory approval process.

SVRA securities class action FDA clinical trial regulatory approval

Sentiment note

The lawsuit alleges the company made false or misleading statements about its MOLBREEVI clinical trial's Biologics License Application, suggesting potential regulatory challenges and potential need for additional capital raising

Negative Oct 30, 2025 • 23:32 UTC GlobeNewswire Inc. • Rosen Law Firm

SVRA FINAL DEADLINE: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Savara Inc. Investors to Secure Counsel Before Important November 7 Deadline in Securities Class Action– SVRA

Rosen Law Firm alerts Savara Inc. investors about a securities class action lawsuit regarding potential misleading statements about a clinical trial's Biologics License Application and FDA approval timeline.

SVRA securities class action FDA clinical trial investor rights

Sentiment note

The lawsuit alleges the company made false or misleading statements about its MOLBREEVI clinical trial, FDA approval prospects, and potential need for additional capital, suggesting significant regulatory and financial challenges

Negative Oct 30, 2025 • 17:46 UTC GlobeNewswire Inc. • Law Offices Of Howard G. Smith

DEADLINE ALERT for QMCO, TROX, SVRA, FLYE: Law Offices of Howard G. Smith Reminds Shareholders of Opportunity to Lead Securities Fraud Class Actions

Law firm alerts investors about potential securities fraud class action lawsuits for four companies, highlighting alleged misleading statements and financial irregularities during specific time periods.

QMCO TROX SVRA FLYE securities fraud class action investor lawsuit financial misrepresentation

Sentiment note

Suggested to have insufficient regulatory documentation for drug approval and potential capital raising needs

Negative Oct 29, 2025 • 20:48 UTC Benzinga • Prnewswire

Savara Inc. (SVRA) Shareholders Investors Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit

Glancy Prongay & Murray LLP is announcing a securities fraud class action lawsuit against Savara Inc., alleging the company misled investors about its MOLBREEVI BLA regulatory approval process between March 2024 and May 2025.

SVRA securities fraud lawsuit FDA approval regulatory disclosure

Sentiment note

The lawsuit alleges the company failed to disclose critical information about its MOLBREEVI BLA submission, potentially misleading investors about its business prospects, regulatory approval likelihood, and potential need for additional capital

Negative Oct 29, 2025 • 01:39 UTC GlobeNewswire Inc. • Pomerantz Llp

LEVI & KORSINSKY ISSUES CORRECTION: Securities Fraud Class Action Against Savara Inc.

A securities fraud class action lawsuit has been filed against Savara Inc. alleging false statements and concealment regarding the MOLBREEVI BLA regulatory approval process, potentially impacting shareholders between March 4, 2024 and May 23, 2025.

SVRA securities fraud class action regulatory approval FDA shareholder lawsuit

Sentiment note

The lawsuit alleges the company made false statements about its MOLBREEVI BLA regulatory approval, potentially misled investors about its timeline, and increased likelihood of needing additional capital, which suggests significant corporate governance and financial transparency issues